@article{fcccb47972f64beb8870a6251ae35df1,
title = "Associations between retinal nerve fiber layer abnormalities and optic nerve examination",
abstract = "Objective:: Retinal nerve fiber layer (RNFL) abnormalities detected by optical coherence tomography (OCT) are useful markers for axonal loss and visual dysfunction in multiple sclerosis (MS), but their role in routine clinical management is not well-studied. Methods:: Clinical and OCT examinations were performed on 240 patients attending a neurology clinic. Using OCT 5th percentile to define abnormal RNFL thickness, we compared eyes classified by neurologists as having optic atrophy to RNFL thickness, and afferent pupillary defect (APD) to RNFL thickness ratios of eye pairs. Results:: Mean RNFL thickness was less in eyes classified by neurologists as having optic atrophy (79.4 ± 21 μm; n = 63) vs those without (97.0 ± 15 μm; n = 417; p < 0.001, t test) and in eyes with an APD (84.1 ± 16 μm; n = 44) than without an APD (95.8 ± 17 μm; n = 436; p < 0.001). Physicians' diagnostic accuracy for detecting pallor in eyes with an abnormal RNFL thickness was 79% (sensitivity = 0.56; specificity = 0.82). Accuracy for detecting a RAPD in patients with mean RNFL ratio (affected eye to unaffected eye) <0.90 was 73% (sensitivity = 0.30; specificity = 0.86). Ability to detect visual pathway injury via assessment of atrophy and APD differed between neurologists. Conclusions:: OCT reveals RNFL abnormality in many patients in whom eyes are not classified by neurologic examiners as having optic atrophy. Further study is needed to define the role of OCT measures in the context of examinations for optic atrophy and APD by neuroophthalmologists. OCT-measured RNFL thickness is likely to have an important future role in the clinical setting.",
author = "D. Cettomai and G. Hiremath and J. Ratchford and A. Venkatesan and Benjamin Greenberg and J. McGready and Pardo, {C. A.} and Kerr, {D. A.} and Elliot Frohman and Balcer, {L. J.} and McArthur, {J. C.} and Calabresi, {P. A.}",
note = "Funding Information: D. Cettomai has received research/salary support from the NIH/Johns Hopkins Pre-Doctoral Clinical Research Training Program (T32), the University of California, San Francisco, and the Doris Duke Foundation. Dr. Hiremath reports no disclosures. Dr. Ratchford serves as a consultant for Sun Pharmaceutical Industries Ltd. and receives research support from Novartis. Dr. Venkatesan serves on a scientific advisory board for GlaxoSmithKline and receives research support from the NIH ( NIDA K08 DA022946 [PI] ) and the Howard Hughes Medical Institute. Dr. Greenberg has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., and EMD Serono, Inc.; serves as a consultant for and holds equity in DioGenix, Inc.; receives research support from the University of Texas Southwestern, the Guthy Jackson Foundation, and the Accelerated Cure Project; and has given expert testimony in medico-legal cases. Dr. McGready and Dr. Pardo report no disclosures. Dr. Kerr has received funding for travel and speaker honoraria from Teva Pharmaceutical Industries Ltd. and Biogen Idec; served as an Associate Editor for the Annals of Neurology ; is an author on patents re: Strategies to create immune tolerance of CNS allografts and cell-based compositions and Methods for treating conditions of the nervous system; and is a founder and equity holder and served as Chief Scientific Consultant for Nerveda, Inc. Dr. Frohman has served on speakers' bureaus for and received funding for travel and speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., and Bayer Schering Pharma; and has served as a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Athena Diagnostics, Inc., and Abbott. Dr. Balcer serves on a scientific advisory board for and has received funding for travel and speaker honoraria from Biogen Idec and receives research support from the NIH ( NEI K24 EY 018136 [PI] ) and the National Multiple Sclerosis Society. Dr. McArthur serves as an unpaid consultant to Allergan, Inc., Pfizer Inc., and Biogen Idec; receives royalties from the publication of Current Therapy in Neurologic Disease, 7th edition (Mosby, 2006); is an author on patents re: Device for thermal stimulation of small neural fibers and Immunophilin ligand treatment of antiretroviral toxic neuropathy; and receives research support from Biogen Idec, the NIH ( R01 MH075673 [PI], RO1 NS44807 [PI], RO1 NS49465 [PI], and R01 MH067831 [Co-I] ), the National Multiple Sclerosis Society, and the Foundation for Peripheral Neuropathy. Dr. Calabresi is an author on a patent re: Role of Kv1.3 as neuroprotective; has served as a consultant for Novartis, EMD Serono, Inc., Teva Pharmaceutical Industries Ltd., Biogen Idec, Vertex Pharmaceuticals, Amplimmune, Inc., Centocor Ortho Biotech Inc., Genentech, Inc., and Novo Nordisk; and has received research support from EMD Serono, Inc., Teva Pharmaceutical Industries Ltd., Biogen Idec, Genentech, Inc., Bayer Schering Pharma, Vertex Pharmaceuticals, the NIH ( NINDS NS RO-1 041435 [PI] ), and the National Multiple Sclerosis Society.",
year = "2010",
month = oct,
day = "12",
doi = "10.1212/WNL.0b013e3181f735bd",
language = "English (US)",
volume = "75",
pages = "1318--1325",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "15",
}